Roche's Pegasys Gains Hepatitis B Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears peginterferon alfa-2a for treatment of HBeAg-positive and negative chronic hepatitis B patients; approval is based on two Phase III head-to-head trials with GlaxoSmithKline's Epivir-HBV. Roche is highlighting Pegasys' limited duration of treatment relative to other hepatitis B therapies.